Kura Oncology Inc SEC Filings

Troy E. Wilson, President and CEO and a director of Kura Oncology (KURA), reported the vesting of performance-based restricted stock units and a related sell-to-cover tax sale. On 09/27/2025 182,500 shares were acquired upon the vesting of 1/6th of PSUs granted May 31, 2023 (price reported $0). On 09/29/2025 the reporting person sold 36,615 shares at $8.9422 per share to cover taxes, leaving 246,853 shares held directly. The filing also shows 279,194 shares held indirectly by One Fish Two Fish Revocable Trust and 300,000 shares held indirectly by Lorax Charitable Remainder Unitrust.

Kura Oncology SVP, Finance & Accounting Thomas Doyle acquired 24,966 shares of Kura common stock on 09/27/2025 at a reported price of $0, increasing his direct holdings to 114,370 shares. On 09/29/2025 he sold 4,541 shares at $8.9422 per share as a sell-to-cover transaction to satisfy taxes tied to the vesting of 1/6th of performance-based restricted stock units (PSUs). The filing notes that one performance milestone was achieved on 09/27/2025, triggering the vesting event for that tranche; the Reporting Person also reports 500 shares indirectly held in a spouse's 401(k). After the transactions the Reporting Person beneficially owns 109,829 shares.

Reporting person: Troy Edward Wilson, President & CEO and a director of Kura Oncology, Inc. (KURA). On 09/08/2025 he acquired 50,000 shares of the issuer's common stock in multiple trades at a weighted average purchase price of $8.2029 per share. After the purchase, Mr. Wilson beneficially owns 100,968 shares directly and holds additional indirect interests of 279,194 shares through the One Fish Two Fish Revocable Trust and 300,000 shares through the Lorax Charitable Remainder Unitrust. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Wilson on 09/09/2025. The filing discloses that trade prices ranged from $8.135 to $8.24 and that the reported price is a weighted average.

Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 6,200,000 shares of Kura Oncology common stock, representing 7.14% of the class based on 86,797,185 shares outstanding as reported by the issuer. The shares are directly held by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager and exercises shared voting and dispositive power over the reported shares. Both Armistice Capital and Mr. Boyd state no sole voting or dispositive power and that the Master Fund disclaims beneficial ownership due to the manager’s control under the investment management agreement. The filing is made on behalf of both reporting persons under a joint filing statement.

Troy Edward Wilson, President, CEO and a director of Kura Oncology, purchased additional common stock on 08/12/2025 and 08/13/2025. On 08/12/2025 he acquired 36,506 shares at a weighted average price of $5.8505. On 08/13/2025 he acquired 13,494 shares at a weighted average price of $6.6417. Following these purchases the reporting person directly beneficially owns 50,968 shares. The filing discloses indirect holdings of 279,194 shares held by the One Fish Two Fish Revocable Trust and 300,000 shares held by the Lorax Charitable Remainder Unitrust. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 08/13/2025. Explanatory notes state the trades were executed in multiple fills and include 409 shares previously acquired on 05/17/2024 under the issuer's Employee Stock Purchase Plan.

EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman jointly reported beneficial ownership of Kura Oncology common stock on a Schedule 13G/A. EcoR1 and Mr. Nodelman each report shared voting and shared dispositive power over 4,200,000 shares, representing 4.8% of the outstanding common stock, while the Qualified Fund reports shared voting and dispositive power over 3,937,232 shares, representing 4.5%.

The filing states these interests were acquired and are held in the ordinary course of business and were not acquired to influence control of the issuer. The filing also discloses that EcoR1 is the general partner and investment adviser to funds including the Qualified Fund and that Mr. Nodelman is the control person of EcoR1. Percentages are calculated using 86,797,185 shares outstanding as reported in the issuer's quarter-end filing.

Kura Oncology (KURA) filed an 8-K announcing updated Phase 1a/1b results for ziftomenib, its oral menin inhibitor, from the KOMET-007 study in newly diagnosed AML patients with NPM1-m or KMT2A-r mutations. The 600 mg QD dose given with standard 7+3 chemotherapy produced robust composite complete remission (CRc) of 92 % (65/71) and complete remission (CR) of 80 % (57/71), with similar efficacy across both genetic sub-groups (CRc: 93 % NPM1-m, 89 % KMT2A-r). MRD-negative CR rates reached 71 % for NPM1-m and 88 % for KMT2A-r, achieved in roughly 4–5 weeks.

Durability signals are emerging: median CR duration and overall survival have not yet been reached in NPM1-m patients after a median 24.9-week follow-up; KMT2A-r patients show a median CR duration of 25.6 weeks with OS not reached. Survival remains high, with 96 % (NPM1-m) and 88 % (KMT2A-r) alive and on study.

The pooled safety set (n = 82) showed a profile consistent with prior data. ≥Grade 3 treatment-related adverse events >10 % included febrile neutropenia (15 %), thrombocytopenia (15 %), anemia (11 %) and neutropenia (11 %). Importantly, there were no dose-limiting toxicities, meaningful QTc prolongation, drug–drug interactions or additive myelosuppression; a single grade-3 differentiation syndrome case was successfully managed.

Kura plans to initiate the KOMET-017 randomized Phase 3 trials (intensive and non-intensive chemo backbones) in 2H 2025. The company also hosted a virtual investor event on 18 Jun 2025 (Exhibit 99.1) to discuss the data.